Latent Tuberculosis: 4 Months of Rifampicin compared to 9 Months of Isoniazid

被引：0
|
作者：
Manych, Matthias
机构：
来源：
PNEUMOLOGIE | 2020年 / 74卷 / 06期
关键词：
D O I：
10.1055/a-1122-2660
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Die empfohlene Therapie latenter Tuberkuloseinfektionen (LTBI) besteht in Europa aus einer 6-9-monatigen und in Nordamerika aus einer 9-monatigen Einnahme von Isoniazid. Zunehmend ruckt Rifampicin mit einer kurzeren Therapiedauer in den Fokus. Ein kanadisches Team verglich Isoniazid uber 9 Monate mit einer Rifampicin-Therapie uber 4 Monate in Bezug Hepatotoxizitat, Therapietreue und direkte Gesundheitskosten.
引用
收藏
页码：327 / 327
页数：1
相关论文
共 50 条
  • [1] Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection
    Menzies, Dick
    Long, Richard
    Trajman, Anete
    Dion, Marie-Josee
    Yang, Jae
    Al Jahdali, Hamdan
    Memish, Ziad
    Khan, Kamran
    Gardam, Michael
    Hoeppner, Vernon
    Benedetti, Andrea
    Schwartzman, Kevin
    [J]. ANNALS OF INTERNAL MEDICINE, 2008, 149 (10) : 689 - U4
  • [2] Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine
    McClintock, Adelaide H.
    Eastment, McKenna
    McKinney, Christy M.
    Pitney, Caroline L.
    Narita, Masahiro
    Park, David R.
    Dhanireddy, Shireesha
    Molnar, Alexandra
    [J]. BMC INFECTIOUS DISEASES, 2017, 17
  • [3] Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine
    Adelaide H. McClintock
    McKenna Eastment
    Christy M. McKinney
    Caroline L. Pitney
    Masahiro Narita
    David R. Park
    Shireesha Dhanireddy
    Alexandra Molnar
    [J]. BMC Infectious Diseases, 17
  • [4] Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
    Wendy A. Lai
    Kaitlyn Brethour
    Olivia D’Silva
    Richard E. Chaisson
    Alice A. Zwerling
    [J]. BMC Public Health, 22
  • [5] Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
    Lai, Wendy A. A.
    Brethour, Kaitlyn
    D'Silva, Olivia
    Chaisson, Richard E. E.
    Zwerling, Alice A. A.
    [J]. BMC PUBLIC HEALTH, 2022, 22 (01)
  • [6] Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children
    Bright-Thomas, R.
    Nandwani, S.
    Smith, J.
    Morris, J. A.
    Ormerod, L. P.
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2010, 95 (08) : 600 - 602
  • [7] Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults
    Menzies, D.
    Adjobimey, M.
    Ruslami, R.
    Trajman, A.
    Sow, O.
    Kim, H.
    Baah, J. Obeng
    Marks, G. B.
    Long, R.
    Hoeppner, V.
    Elwood, K.
    Al-Jahdali, H.
    Gninafon, M.
    Apriani, L.
    Koesoemadinata, R. C.
    Kritski, A.
    Rolla, V.
    Bah, B.
    Camara, A.
    Boakye, I.
    Cook, V. J.
    Goldberg, H.
    Valiquette, C.
    Hornby, K.
    Dion, M. -J.
    Li, P. -Z.
    Hill, P. C.
    Schwartzman, K.
    Benedetti, A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (05): : 440 - 453
  • [8] Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection
    Sterling, Timothy R.
    Villarino, M. Elsa
    Borisov, Andrey S.
    Shang, Nong
    Gordin, Fred
    Bliven-Sizemore, Erin
    Hackman, Judith
    Hamilton, Carol Dukes
    Menzies, Dick
    Kerrigan, Amy
    Weis, Stephen E.
    Weiner, Marc
    Wing, Diane
    Conde, Marcus B.
    Bozeman, Lorna
    Horsburgh, C. Robert, Jr.
    Chaisson, Richard E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (23): : 2155 - 2166
  • [9] Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection
    J. M. Pina
    L. Clotet
    A. Ferrer
    M. R. Sala
    P. Garrido
    L. Salleras
    A. Domínguez
    [J]. European Journal of Clinical Microbiology & Infectious Diseases, 2013, 32 : 647 - 655
  • [10] Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection
    Pina, J. M.
    Clotet, L.
    Ferrer, A.
    Sala, M. R.
    Garrido, P.
    Salleras, L.
    Dominguez, A.
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2013, 32 (05) : 647 - 655
12345